Background: Intensified insulin delivery using multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) is recommended in children with type 1 diabetes (T1D) to achieve good metabolic control. Objective: To examine the frequency of pump usage in T1D children treated in SWEET (Better control in Paediatric and Adolescent diabeteS: Working to crEate CEnTers of Reference) centers and to compare metabolic control between patients treated with CSII vs MDI. Methods: This study included 16 570 T1D children participating in the SWEET prospective, multicenter, standardized diabetes patient registry. Datasets were aggregated over the most recent year of treatment for each patient. Data were collected until March 2016. To assess the organization of pump therapy a survey was carried out.
| INTRODUCTION
Many clinical trials have demonstrated that tight blood glucose control reduces the risk of developing microvascular diabetes complications in all patients with type 1 diabetes (T1D). The beneficial effects of reducing cardiovascular disease, retinopathy, nephropathy, and neuropathy are well documented in the DCCT-EDIC study. 1, 2 In order to reduce these long-term effects of hyperglycemia, glucose control should be optimized as early as possible in the course of type 1 diabetes. 3 An intensified insulin regimen is necessary in T1D patients to achieve near-normal glucose control. However, only a relatively small percentage of patients achieve these glycemic targets. 4 Continuous subcutaneous insulin infusion (CSII) is a very effective treatment modality, which is safe and widely used in children and adolescents with T1D. There are many benefits for CSII therapy in children and adolescents such as: optimum blood glucose control, reduction of recurrent/severe and disabling hypoglycemia and improved quality of life. 5 Insulin pump therapy allows a greater flexibility in insulin dosing and meal planning, when compared with multiple daily injections (MDI). 6, 7 Meta-analyses demonstrate a reduction in glycated hemoglobin A1c (HbA1c) and severe hypoglycemia with CSII therapy compared to MDI. 8 Following the evidence-based demonstrations of the benefits of CSII therapy, the first international consensus statement of insulin pump indications and practice in children was created in 2007. 9 Insulin pump therapy in the pediatric age group has markedly increased in the last decade (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . However, use of CSII remains limited in some European countries. The main reasons are a lack of funding by National Healthcare Insurance Systems, low number of trained physicians to deliver insulin pump therapy and a lack of trained diabetes educators. 10 We hypothesized that children with T1D treated in SWEET (Better control in Paediatric and Adolescent diabeteS: Working to crEate CEnTers of Reference) centers with CSII had a better metabolic control than those using MDI. The aims of this study are: to examine the frequency of pump usage in T1D children treated in SWEET centers and to compare the cross-sectional metabolic control between patients treated with CSII vs. MDI.
| METHODS
The analysis is based on data from SWEET, a prospective, multicen- were excluded. For the present analysis, patients with type 1 diabetes, aged 0-18 y and with a diabetes duration ≥1 y were included. The exclusion criterion was missing insulin therapy ( Figure 1 ). Datasets were aggregated over the most recent year of treatment for each patient. Three SWEET centers were excluded from analysis due to incomplete data. The final cohort available for analysis was n = 16 570 children with type 1 diabetes treated in 46 centers. Diabetes control was assessed by glycated hemoglobin value (HbAlc), which was measured locally in each center. In order to adjust for differences between laboratories, multiple of the mean (MOM) method was used to mathematically standardize HbA1c values to the reference range of the Diabetes Control and Complications Trial [DCCT, 21-43 mmol/mol (4-6%)]. 11 Insulin pump usage was defined as at least one visit with pump therapy. Body mass index standard deviation score (BMI-SDS) was measured using the World Health Organization (WHO) charts. 12 Further analysis was performed in three subgroups according to age: 0-<6, 6-<12, 12-18 y. Diabetes duration was grouped into <5 and ≥5 y. Center size was defined as the number of patients in each center. Children were divided into two groups depending on the method of insulin therapy: insulin pump (CSII) or MDI. We evaluated the frequency of insulin pump usage in the different age groups and compared outcomes of diabetes control between children using insulin pump therapy or MDI.
In order to collect data on the organization of pump therapy in SWEET centers, each center was invited to complete an online survey. The questions included were the following: presence of National Pump Registry, reimbursement of insulin pump therapy, initiation and discontinuation of pump treatment and 24-h access to a pediatric diabetes team member. Participants were able to mark only one answer for each question. The survey was completed by 32 centers (67%) and the results are seen in Table 1 . 
| STATISTICAL ANALYSIS

| RESULTS
The current analysis included 16 570 participants (51.5% male). Results showed that 44.4% of T1D children and adolescents were treated with CSII (varying from 0% to 90% per center). There was comparable percentage of pump users in European countries (45.8%) and in countries outside Europe (39.3%).
Median age was
Center size did not influence pump use in the full group (r = 0.25, P = .088). In a logistic regression analysis adjusting for age categories, gender and diabetes duration categories, the use of pump was associated with center size with an estimated odd ratio 1.51 (1.47-1.55), P < .0001. This means that for every 500 patient increase in center size, the probability of a child being on a pump increases by 51%. There was no significant correlation between proportion of CSII users in each center and HbA1c (r = −0.26, P = .084).
For the countries represented in this cohort, the mean diabetes- HbA1c was lower in all age groups using CSII (Figure 3 ). Linear regression model analysis, adjusting for age, gender and diabetes duration showed that HbA1c remained higher in children treated with MDI compared to CSII (P < .0001). Similar results were shown in linear regression analysis adjusting for gender and diabetes duration in age-related subgroups. In all age groups, HbA1c was higher in children treated with MDI compared to CSII (P < .0001).
Children using CSII therapy used lower total daily insulin dose compared to youth treated with MDI [CSII: 0.83 (0.66; 1.02) U/kg/d vs MDI: 0.9 (0.7; 1.13) U/kg/d, P < .0001) and daily insulin dose was lower in both groups of youth 6-<12 y and 12-18 y old treated with CSII ( Figure 3) . In a linear regression model adjusting for age, gender and diabetes duration, children treated with MDI had higher daily insulin dose (U/kg/d) than subjects using CSII (P < .0001).
The unadjusted BMI-SDS was higher in MDI group "0.51 (−0.14;
1.18)" compared to CSII "0.58 [−0.05, 1.2]", P = .000. The BMI-SDS was higher only in children with CSII and 6->12 y of age ( Figure 3 ).
Linear regression analysis adjusting for diabetes duration showed a similar BMI-SDS in both treatment groups (P = 0.399).
| DISCUSSION
Current results showed that insulin pump therapy was used in 44.4% children aged 0-18 y treated in the SWEET centers. The data represents only the frequency of pump therapy in the SWEET centers, and does not necessarily reflect the management of diabetes by country.
Our survey showed that national data on pump use are present only in 38% of countries represented in our SWEET group. Owing to lack of national data, the analysis of an overall use of CSII in SWEET countries was not possible.
The prevalence of CSII therapy usage has increased in many countries, but there are still differences in CSII usage among countries. 10 The overall use of insulin pumps in patients 0-18 y was 74% (2011) in Slovenia, 7 and 58-65% (2015) in United States. 15 The data from three large registries of pediatric type 1 diabetes patients ana- Different factors may influence frequency of pump use in a center. Insulin pump therapy is more expensive than injections. 20 Therefore, socioeconomic status of families influences the choice of the method of diabetes management in T1D children, especially when there is inadequate or no reimbursement of these devices by national healthcare systems or insurance companies. 5, 21 Our survey showed, that in one third of the centers, costs of CSII therapy are shared by insurance and family or fully covered by family. Moreover, we noted a significant correlation between the proportion of pump users in each center and the diabetes-related health care expenditure per person with diabetes per country. The association between low socioeconomic factors and low frequency of CSII usage was confirmed by other research. 22 In T1D therapy, systematic reviews of costeffectiveness showed a superiority of CSII over MDI. CSII therapy was associated with an improvement in both global life expectancy and quality-adjusted life expectancy. This was achieved by a decrease in HbA1c and by a lower number of hypoglycemia episodes in this group. 23 Our results indicate differences between centers. The correlation did not show any impact of center size on pump usage, but after adjustment for age, sex and diabetes duration we noted that insulin pump therapy was more often used in larger centers. Potential reasons for lower CSII usage in smaller sized center may include organization of diabetes care, insufficient number of physicians specialized in pump therapy or low number of trained diabetes educators. 24 .
However, in France no significant variation in the rate of CSII was observed according to the size of the centers, although the frequency of pump use remained extremely variable, ranging from 1.3 to 53% of T1D children. 19 Diabetes education of T1D children and their families is an essential part of diabetes care with effects on diabetes outcome. 25 It is well known from clinical practice that education and training for patients using CSII therapy is more time consuming, compared to education for those using MDI and this influences work organization in diabetes centers. The results of our survey also emphasize individual approach to pump therapy and work organization in different centers. As seen in Table 1 most centers use an individual approach when starting pump, and the majority of pump starts are based in the outpatient clinic. A 24 h hotline with access to experts in pump therapy is common, whereas guidelines to discontinue insulin pump therapy in non-compliant patients was limited.
Ideally multidisciplinary teams supporting pump users, should contain a critical mass of staff (doctors, nurses, dieticians, and diabetes educators) with appropriate ongoing education in CSII therapy. 26 Our results should be taken with caution because we have not performed any in depth analysis assessing differences in the organization of work in diabetes centers.
The age-related frequency of CSII use differs across countries.
Pump therapy is commonly used in children diagnosed before 6 y of age and is associated with better long-term metabolic control. 27 In our group, CSII therapy was more frequently used in the youngest children less than 6-y-old (52%), than in teenagers over 12 y (42%).
Similar results were reported in the DPV register. 16 In this study, 74% of children less than 6-y-old received insulin pump therapy, compared with 35-40% of older participants. The highest frequency of pump use in the youngest children was also noted in the NPDA register. 15 Conversely, the highest frequency of pump users was shown in teenagers in the T1D register. 16 Observed differences may indicate that different government funding arrangements for insulin pumps (or diabetes-related health care expenditure), may play a significant role in those who are offered pump therapy vs those who are not.
Our results showed no gender-related difference in pump use but further subgroup analysis indicated statistically lower use of insulin pump in boys less than 6-y-old. One may speculate that young boys are busier than girls and they may be inclined to remove infusion sets during vigorous physical activities. The parents may also think these young boys cannot cope with a pump before they try it. Interestingly other studies also noted that boys were treated with a pump less often compared to girls. 16 In our study, children treated with CSII reported better metabolic control expressed by lower HbA1c. Similar results were noted in all three age groups. After adjustment for age, sex and diabetes duration, HbA1c was 0.5% lower in the CSII group compared with the MDI group. Both groups of younger children (<6 and 6-<12 y), using 28 and better metabolic control is noted by others. 5 In our study the regression analysis showed that children using CSII therapy, had lower insulin dosage and similar BMI-SDS comparing with patients treated with MDI. Flexibility of lifestyle and eating habits in patients using CSII may encourage a greater focus on food intake and cause a weight gain especially in teenagers. Excess weight gain in T1D patients was associated with sustained increases in central obesity, insulin resistance, dyslipidemia, blood pressure, and atherosclerosis. 29 We report a significant increase in BMI-SDS, only in children aged 6->12 y using CSII; whereas in younger and older patients, no difference was noted between pump users and children using injections.
A limitation of our study is lack of analysis of frequency of hypoglycemia and ketoacidosis between CSII and MDI patients. The group that used CSII included anyone who had been on a pump without a separate analysis depending on the duration of CSII therapy. Furthermore, we have not performed any further analysis concerning influence of some factors such as: work organization, health care service offered by each center or belonging to an ethnic minority, some or all of which may influence frequency and effectiveness of CSII therapy. Another limitation of our study was also not centralized measurement of HbA1c, which may affect the results. However, in order to adjust for differences between laboratories, we use the MOM-Method.
| CONCLUSIONS
Insulin pump therapy is offered by most SWEET centers and is used on average by 44.4% of patients with comparable percentage of pump users in European and non-European countries. The SWEET centers are a heterogeneous group. The differences among centers for example, the number or age of T1D patients and the national diabetes-related health care expenditure affect the frequency of use of this modern technology. Despite the heterogeneity of centers, T1D children in SWEET achieve good metabolic control; especially those in the younger age groups and those treated with insulin pumps. Further studies evaluating work organization, health care service in each center are needed to identify reversible factors, which may affect diabetes control.
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